Pharmaceutical News

RSS

Prescription and OTC pills may increase unhealthy behavior

The first FDA-approved over-the-counter weight loss pill, has hit shelves nationwide.

17 Jun 2007

Need for a better system of drug evaluation

The current drug surveillance system needs to be fixed, argues an editorial in the British Medical Journal.

17 Jun 2007

Does Alli work?

The first and only over-the-counter product for weight loss approved by the Food and Drug Administration will be available Friday, June 15.

17 Jun 2007

Doctor cautions on use of Tamiflu

In the British Medical Journal a senior doctor advises caution over the use of the antiviral drug oseltamivir (Tamiflu).

17 Jun 2007

Solvay Pharmaceuticals submits supplemental NDA for AndroGel

Solvay Pharmaceuticals, Inc., has announced that it submitted a supplemental New Drug Application (sNDA) for AndroGel (testosterone gel) 1% CIII to the U.S. Food and Drug Administration (FDA) for treatment in male adolescents ages 13-17 years old with primary or secondary hypogonadism.

17 Jun 2007

New era of treatment for rheumatoid arthritis

Three new drugs for rheumatoid arthritis (RA) have ushered in a new era of treatment for this difficult and debilitating condition.

16 Jun 2007

Don't flush old or unused medications

Your spring cleaning is done. Or is it? Did you clean out your medicine cabinet? Before you flush old or unused medication, precautions need to be taken.

16 Jun 2007

Irrational use of medicines is a major problem all over the world

The World Health Organization (WHO) and many other bodies are concentrating on improving the use of medicines. Problem-based teaching of Pharmacology and Therapeutics to undergraduate medical students has been recognized as a key intervention to improve the use of medicines.

15 Jun 2007

Zimulti (rimonabant) gets the thumbs down from FDA advisory panel

An advisory panel to the Food and Drug Administration (FDA) in the U.S. have unanimously voted that the federal agency should refuse approval for a new weight loss drug.

14 Jun 2007

Neurocrine Biosciences announces resubmission of NDA for Indiplon capsules

Neurocrine Biosciences, Inc. has announced that they have resubmitted its New Drug Application (NDA) for indiplon 5 mg and 10 mg capsules for the treatment of insomnia in both adult and elderly patients to the U.S. Food and Drug Administration (FDA).

14 Jun 2007

Priority review granted for oral formulation of HYCAMTIN (topotecan)

GlaxoSmithKline (GSK) has announced that its new drug application (NDA) for ORAL HYCAMTIN (topotecan) capsules, a treatment for relapsed small cell lung cancer (SCLC), has been granted Priority Review by the United States Food and Drug Administration (FDA).

14 Jun 2007

Eurand files NDA for Zentase for the treatment of exocrine pancreatic insufficiency

Eurand has announced that Eurand Pharmaceuticals Ltd. initiated the rolling submission of its new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for Zentase for the treatment of Exocrine Pancreatic Insufficiency (EPI). Zentase (formerly EUR-1008), the company's lead product candidate, has been granted fast-track designation by the FDA.

14 Jun 2007

Alli weight loss drug on the U.S. market soon

Alli which is produced by GlaxoSmithKline will be available to consumers in America next week following a 150 million dollar advertising campaign to promote the non-prescription drug.

12 Jun 2007

FDA decision over new obesity drug hangs in the balance

The Food and Drug Administration (FDA) in the United States appears to be holding back on it's decision to grant approval for a weight loss drug.

11 Jun 2007

Buyers beware of cosmeceuticals!

Consumers are spending big bucks on a new category of anti-wrinkle creams and lotions - cosmeceuticals.

8 Jun 2007

Drug giant accused of using stand-over tactics about Avandia

The controversy surrounding GlaxoSmithKline's (GSK) diabetes drug Avandia has been exacerbated by claims from a medical expert that he was threatened with a $4bn lawsuit to try to silence his criticisms of the company's controversial diabetes drug.

7 Jun 2007

CRT and Manchester University announce biomarker alliance with AstraZeneca

Cancer Research Technology Limited (CRT), the cancer-focused development and commercialisation company, and The University of Manchester today announce the establishment of an alliance with AstraZeneca to develop serological pharmacodynamic (PD) biomarkers.

4 Jun 2007